0000000000379795

AUTHOR

P Rogliani

showing 2 related works from this author

Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

2019

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaTreatment outcomeMEDLINEOmalizumabOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin Eeosinophil Omalizumab anti-IgE asthmaLeukocyte CountText miningForced Expiratory VolumeInternal medicineEosinophiliamedicineHumansImmunology and AllergyAnti-Asthmatic AgentsBlood eosinophilAgedRetrospective StudiesAsthmabiologybusiness.industryRetrospective cohort studyMiddle AgedasthmaPrognosismedicine.diseaseEosinophilsTreatment Outcomeinflammationbiology.proteinFemalebusinessmedicine.drug
researchProduct

Corrigendum to “Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up” (Respiratory Medicine (2019) 153 (68–75),…

2019

The authors regret that the affiliations of two authors were incorrectly reported. The right affiliation of Fabiano di Marco is: “Department of Health Science, University of Milan, Respiratory Unit, Pope John XXIII Hospital, Bergamo, Italy”; the right affiliation of Pierachille Santus is: “Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Milan, Italy”. The authors would like to apologise for any inconvenience caused.

health-careSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct